Fig. 1

Restored MEG3 stimulates the apoptosis of Molm13 cells and increases the sensitivity of Molm13 cells to AraC. A, MEG3 expression in bone marrow samples of AML patients (n = 35) and healthy individuals (n = 35) determined by RT-qPCR. * p < 0.05 compared with healthy individuals. B, MEG3 expression in normal bone marrow cells HS-5 and AML cell lines HL-60 and Molm13 determined by RT-qPCR. * p < 0.05 compared with HS-5 cells. C, MEG3 expression in Molm13 and Molm13 R cells following treatment with AraC at different concentrations determined by RT-qPCR. D, Molm13 and Molm13 R cell viability following treatment with AraC at different concentrations assessed by CCK-8 assay (0 μM AraC was used as the control). E, MEG3 expression in Molm13 cells treated with sh-MEG3-1 and sh-MEG3-2 and Molm13 R cells treated with oe-MEG3-1 determined by RT-qPCR. F, CCK-8 assay was used to detect the viability of Molm13 cells co-treated with 2 μM AraC and sh-MEG3 and Molm13 R cells co-treated with 2 μM AraC and oe-MEG3. G, Flow cytometry was used to detect the apoptosis of Molm13 cells co-treated with 2 μM AraC and sh-MEG3 and Molm13 R cells co-treated with 2 μM AraC and oe-MEG3. H, Western blot analysis was used to measure the expression of Bcl-2, Bax and cleaved caspase-3 proteins in Molm13 cells co-treated with 2 μM AraC and sh-MEG3 and Molm13 R cells co-treated with 2 μM AraC and oe-MEG3. * p < 0.05. Cell experiments were performed three times independently